Safety and Efficacy of up to Eight Years of Continuous Etanercept Therapy in Patients With Juvenile Rheumatoid Arthritis.

The article discusses a study which evaluated the safety and efficacy of eight years etanercept treatment in patients diagnosed with polyarticular-course juvenile rheumatoid arthritis (JRA). The study included JRA patients who were previous participants of a randomized controlled trial (RCT) of etanercept. No cases of opportunistic infections, lupus, lymphomas or deaths were reported among the study population. The study concluded that the acceptable safety profile of etanercept is maintained for up to eight years.